In This Section
Back to Grantees
Loading...
AACR-Novocure grantee elucidates the impact of Tumor Treating Fields on the blood-brain barrier

AACR-Novocure grantee elucidates the impact of Tumor Treating Fields on the blood-brain barrier

Treatment options for brain cancers, including aggressive glioblastoma, are limited despite the availability of several chemotherapeutic drugs due to the inability of these drugs to cross the blood-brain barrier (BBB). AACR-Novocure grantee Dr. Carsten Hagemann and his team showed that the use of low-intensity alternating electric fields known as Tumor Treating Fields (TTFields), an FDA-approved treatment modality, can facilitate drugs crossing the BBB. Using multiple models, they elucidated the mechanisms driving this action.

Bosarge Family Foundation-Waun Ki Hong Scholar Identifies a Novel Target to Mitigate Chemobrain

Bosarge Family Foundation-Waun Ki Hong Scholar Identifies a Novel Target to Mitigate Chemobrain

Chemotherapy-induced cognitive impairment (CICI), also known as chemobrain, can affect up to 75% of patients during treatment. Recipient of the 2019 The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine Alfredo Oliveros, PhD, and his colleagues showed that inhibiting adenosine A2A receptor signaling can prevent cisplatin-induced cognitive impairment.